Table 1 Patients and tumor characteristics (N = 36).

From: Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study

Characteristics No. %
Total 36 100.0%
Age (years)
 Median 58
 Range 38–75
Gender
 Male 25 69.4%
 Female 11 30.6%
Primary lesion
 Gastric 25 69.4%
 Gastroesophageal junction 11 30.6%
Histology
 Adenocarcinoma 31 86.1%
 Adenocarcinoma with other components 4 11.1%
 Mucinous adenocarcinoma 1 2.8%
Differentiation
 Poorly 14 38.9%
 Moderately 17 47.2%
 Highly 2 5.6%
 Unknown 3 8.3%
Her2 status
 Negative 12 33.3%
 Positive 8 22.2%
 Unknown 16 44.4%
Metastasis at Stage IV diagnosis
 Liver 20 55.6%
 Lung(s) 4 11.1%
 Peritoneum 8 22.2%
 Distant lymph node 18 50.0%
No. of metastatic sites
 ≤2 6 16.7%
 >2 30 83.3%
ECOG PS
 0 7 19.4%
 1 24 66.7%
 2 4 11.1%
 3 1 2.8%
  1. (Adenocarcinoma with other components included mucinous adenocarcinoma or signet ring cell carcinoma. Her2 negative status included IHC score 0, 1, 2 without gene amplification in FISH, while positive status included IHC score 2 with gene amplification in FISH. Distant lymph nodes included Supraclavicular lymph nodes, Posterior peritoneum lymph nodes, and other lymph nodes. One patient could have several metastatic lesions and there were some other infrequent metastatic site, such as osseous, adrenal, ovarian metastasis).